These findings are critical for optimizing dosing strategies in longitudinal studies of TfRMAb-based therapeutics, particularly TfRMAb-EPO, given the movement of TfRMAb-based therapeutics into clinical trials for AD (NCT04639050). The gene discussed is EPO; the disease is Alzheimer disease.